The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
We know Lansdown have reduced their holding based on previous updates but we do not know for definite where they sit at the moment, as there has been no further declaration on their position. It is a perplexing picture, but in the meantime, the science continues to be slowly rallying round interferon it would seem, as a potential treatment to stave off the worse symptoms of Covid if administered early enough. COPD use for sng also remains a significant part of the Synairgen equation.
None of this is a guarantee this product will get to market. But a lot of effort is currently being put into getting these trials to a place where some prompt conclusions can be made.
It is going to be an ‘interesting’ and likely nervy few weeks ahead.
Same here. I made the decision to invest because the product makes sense to me, and the science now seems to moving towards this approach more. I will look back later on this time as either being a moment I made a really smart decision or basically I stuffed up. But short of investing less or more here, I think I have made a balanced decision to opt in here based on the research and the risk/reward.
Not that long to find out now.
Allowing for my own confirmation bias here, the potential of the sng treatment seems to be gaining more favourable assessments from those who can speak with authority in this field.
So, the outlook seems to have strengthened, as far as I can see. The sp flies in the face of this, but the science behind sng seems to be holding up. And the results which will seal it one way or another are not that far away.
Good luck, Newbie, hope your family stay well. I’ve gone as far as I want to go, finally, with buying in the dips, though I suspect this may indeed fall further. I’m staying put but good luck with your timing and getting back in at the optimum moment. :-)
Personally, it would seem make sense to me to get the results of the COPD trial out there as soon as possible if they look positive. It would again raise the profile of the company, which I am sure is on the radar of bigger fish anyway, and I would have thought it might encourage someone to start talking more seriously ahead of the results of the home trials.
Just my view.
I think a few of us bought in recently on the basis of results coming sooner than it now transpires they will. My guess, for what it’s worth, is this share, with unknowable forces also operating in the background at the moment, will possibly splutter along where it is and may well dip further until results get significantly closer. This will likely test the resolve a bit, unless you opt to see this as a chance to average down if you believe in the product.
As far as I’m concerned, I think the evidence elsewhere suggests this product should work, and be of benefit early in the treatment cycle of Covid. It has other significant potential applications. There is still a lot of work to do and a way to go. But nothing so far seems to be closing the door on this being successful within a reasonable time frame. Here’s hoping.
It seems the research and evidence is focusing in on this key issue, and it seems to me that the team are running with the ball here, inasmuch as their home trial should hopefully demonstrate that sng works well with the right timing. It seems to me, they could just be playing a blinder here. Let’s hope so.
Thanks for your time to reply Ghia, much appreciated.
From what I can see, the science behind Sng is long standing and impressive, and I believe these trials are being conducted with the sort of integrity and savvy that should render them productive and reliable. And hopefully bring a marketable outcome for Sng.
Irrespective of this, the COPD aspect to this remains in the background, which may still prove to be a more certain, enduring market for this product over time. No one knows where the world will be with Covid in 6 months’ time.
If nothing else, it has propelled Synairgen forward in its efforts to get their product out there.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30176-6/fulltext
Furstly I should acknowledge this was posted on the Advfn site with thanks to them, but I’m not sure if it has appeared here.
From my understanding of this, which may be incorrect, this would seem to offer an explanation why the home trials route has been inserted into the Sng research. The article seems to indicate that, given early as early as possible in the development of the illness, a product like sng would have a positive effect, but later in the illness, conversely it could have a detrimental effect.
There are undoubtedly more knowledgeable people here, better placed to assess that article than I am, so would be grateful for their thoughts and opinions.
From what I can see, I believe there is some question of the dosage which needs to be higher than has been previously used, though the increase appears to be tolerated.
At the moment it’s another product dependent, like us, on results.
I would second that.
No one likes someone p***ing on their parade, but personally I don’t think that is what Nolupus is doing here at all. It seems to me he is putting out alternative standpoints and evidence to see how the general conviction in this treatment holds up under that scrutiny. And generally, as I think he would agree, it appears to be doing quite well so far.
There is still a way to go with this, and we will all be making our decisions at some point based on what we read, hear and believe, so my pennyworth is keep it coming, Nolupus, I don’t have to agree with you, but I do genuinely value your input and efforts here.
Fair point, Nolupus! ;-)
It was indeed a small ramp thinly disguised as a deramp ;-)
I think the Sng results will show as positive, there is good evidence out there to suggest interferons can play a part, and the nebuliser route sounds practical.
My chief concern is whether politics and the rush to get something out there, because of the economic and health impact of this virus allied with the amount of potential earnings from a ‘treatment’ will tilt this elsewhere.
The science around Sng seems sound from the little I understand but we shall see if this will be enough in what is a very competitive, probably brutal race to get something proven ( or not so proven, it seems) out making a dollar.
There is, of course, long term, the COPD issue, so I am here, settled in, equally long term, for that to play out.
I’ll have a go ;-)
1.) It won’t work.
2.) It won’t work very well.
3.) No recent direct news means something is not happening, there are delays or problems.
4.) It will work ‘quite’ well, but not enough to generate sufficient interest from anyone for it to move forward.
5) The vaccines work. And all govts opt for those, instead of treatments.
6.) COPD dies out. Or someone comes up with a much better treatment before SNG001 can get to market.
7.) The sky falls in all our heads.
There. :-)
There are clearly risks to investing here. But there are risks in all aspects of life. On balance, this share seems to me to be worth sticking with.
I’ve just had another small top up on that belief.
Here’s hoping.
GLA
Decisions decisions.... well, I’m in here as much as I feel I can reasonably be, so do I spend some more time sitting here with the popcorn watching the price do very little, or shall I go and sit in the garden with a cup of tea, and check in later?
I’m going for the latter, have a good productive day all ;-)
( I’ll probably keep checking in through the morning anyway, as you do)
Probably like a few others on here I’ve just been using the price it’s floating around at the moment to keep quietly topping up. I reckon I’ve finally gone as far with that as I want to go, so it’s now going to be a case from here on in, of just settling in and wait for developments to unfold. Positively, one hopes ;-)
So what are people’s thoughts on these articles in relation to the trials conducted by Synairgen?
It seems to me that the trials we are waiting on are being/have been conducted with the clear mission that ‘Data is king’ as Richard Marsden recently stated. The trials contain the placebo protocol, and whilst the numbers involved appear at first view to be relatively small, I suspect this might have been due to the practical management of the trial amid a pandemic and the urgent time frame required.
Certainly it seems to me to have been better prepared and placed to obtain more stringent evidence than one or two other trials conducted elsewhere, and that results should carry some weight whatever they are.